Effects of lifestyle modifications on cognitive impairments in a mouse model of hypercholesterolemia

Neurosci Lett. 2013 Apr 29:541:193-8. doi: 10.1016/j.neulet.2013.02.043. Epub 2013 Mar 5.

Abstract

Epidemiological studies indicate that high midlife plasma cholesterol levels increases the risk of Alzheimer's disease. Moreover, middle-aged familial hypercholesterolemia (FH) subjects show a particularly high incidence of mild cognitive impairments (MCI). These evidence points to hypercholesterolemia as one of the modifiable risk factors focused on prevention/treatment of cognitive deterioration. The present study draws a comparison between pharmacological (lipid-lowering drug probucol) and non-pharmacological (voluntary running wheel, RW) approaches for the management of hypercholesterolemia and cognitive impairments associated with the low-density lipoprotein receptor-deficient (LDLr(-/-)) mice, a well-established rodent model of FH. We also investigated whether exposure to environmental enrichment (EE), a feasible option to increase physical activity in young mice cohort, from birth to adolescence (PN45) yields long-term behavioral changes in adult LDLr(-/-) mice (PN90). We observed that both probucol and RW significantly decreased total and non-HDL plasma cholesterol levels in LDLr(-/-) mice. Notably, only physical exercise mitigated the spatial memory deficits of LDLr(-/-) mice. In addition, we showed that exposure to EE from birth until the adolescence did not mitigate the spatial memory deficits of adult LDLr(-/-) mice in the object location task, although it induced persistent anxyolitic-like effects in the open field arena. Collectively, our results emphasize the advantages physical exercise, in comparison to lipid-lowering drugs, for the management of cognitive deficits associated with FH.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticholesteremic Agents / pharmacology
  • Anticholesteremic Agents / therapeutic use
  • Cognition Disorders / etiology
  • Cognition Disorders / psychology*
  • Cognition Disorders / therapy
  • Founder Effect
  • Hyperlipoproteinemia Type II / complications
  • Hyperlipoproteinemia Type II / drug therapy
  • Hyperlipoproteinemia Type II / psychology*
  • Mice
  • Mice, Knockout
  • Motor Activity
  • Physical Conditioning, Animal*
  • Probucol / pharmacology
  • Probucol / therapeutic use
  • Receptors, LDL / genetics
  • Social Environment

Substances

  • Anticholesteremic Agents
  • Receptors, LDL
  • Probucol